Source Feed: Ottawa Citizen
Author: Nicole Feriancek
Publication Date: October 25, 2025 - 04:00
Ottawa deserves better than a mayor using choreography | Letters to the Editor
October 25, 2025
That’s not how democracy works. In a healthy process, information comes first, then the so-called spin. In Ottawa, it seems spin came first — and that should concern everyone, no matter where you stand on Lansdowne. The Mayor says construction costs are down, revenues are up, and housing funds are higher — but few within and outside City Hall have seen the data yet. How can that be called accountability? Read More
Unpublished Newswire
Doctors are calling on provinces to bolster addiction treatment services in response to growing opioid use among young people, a crisis they fear will escalate for decades to come if immediate action is not taken.In a Canadian Medical Association Journal (CMAJ) editorial published Monday, physicians Shannon Charlebois and Shawn Kelly say the escalation of opioid use among youth is being overlooked. Existing addiction services, they say, are also inadequate to meet the needs of young people with opioid use disorder, or OUD.
October 27, 2025 - 00:01 | Alanna Smith | The Globe and Mail
The Alberta government is expected to introduce back-to-work legislation on Monday to force striking teachers to return to classrooms after three weeks, raising fears among labour advocates that the province will invoke the Charter’s notwithstanding clause to override workers’ rights. More than 750,000 students have been out of class since Oct. 6, after negotiations between the Alberta Teachers’ Association and the province broke down.
October 26, 2025 - 21:24 | Meera Raman | The Globe and Mail
Health Canada has for the first time approved a disease-modifying drug for Alzheimer’s disease, a watershed moment that offers hope for patients but does not guarantee that the complex and expensive intravenous therapy will be widely available in this country. The federal regulator on Friday granted a conditional authorization for lecanemab, an antibody drug that can slow the progression of the disease for some people with mild cognitive impairment or early-stage dementia owing to Alzheimer’s.
October 26, 2025 - 21:08 | Kelly Grant | The Globe and Mail
Comments
Be the first to comment